China · Series D startup
Funding summaryUpdated 26 Oct 2026
$385Mraised across 3 rounds since 2012, from 3 sources
Each circle is a round, placed by date and sized by amount. The line above is the running total.
Temasek Holdings
Legend Capital
F-Prime CapitalFrom a historical funding record
The busiest backers across the latest rounds. A filled square is a round they joined; a dark one, a round they led.
Missing a round, or an investor who was in one? Tell us.
This firm lists Innovent Biologics as a portfolio company on their own website, but no report of a round names it. They are the firms' own claims, kept apart from the rounds above.
Innovent Biologics's investors include F-Prime Capital, Lilly Asia Ventures, Fidelity Growth Partners Asia, Temasek Holdings and Legend Capital, and 3 more on record.
Innovent Biologics has raised $385M across 3 rounds since 2012.
Innovent Biologics's most recent round was a Series D of $260M in Nov 2016.
Its most recent round, $260M in Nov 2016, is also its largest on record.
Innovent Biologics's first round on record, in Nov 2012, was backed by F-Prime Capital, Lilly Asia Ventures and Fidelity Biosciences and 2 others.
Innovent Biologics's latest named round is a Series D, in Nov 2016.
Innovent Biologics is based in China.
In the same sector, and raised in the last eighteen months.
Search every investor by what they have actually funded, then narrow to your stage and market. Free.
China · 
